Challenges and Opportunities for the Large-Scale Chemoenzymatic Glycoengineering of Therapeutic N-Glycosylated Monoclonal Antibodies

Adelina Ivanova1* and Francesco Falcioni2

1School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom, 2Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Cambridge, United Kingdom

Variability in the glycosylation profile of therapeutic monoclonal antibodies (mAbs), due to recombinant production technologies, leads to inconsistencies in effector functions and pharmacokinetic properties, both batch-to-batch and within single batches. It also poses regulatory concerns over the effectiveness of commercially available formulations. *In vitro* chemoenzymatic glycoengineering of variants displaying a homogeneous glycan profile is a trending strategy for ensuring consistent, controlled, and enhanced therapeutic performance, but reported successes are largely limited to small-scale applications. The major challenges for the industrial-scale introduction of the technique stem from the need for activated sugar donors, which can participate in undesired side reactions, and from the economic cost of the additional enzymatic steps and purification stages. While recent developments within the area address some of these obstacles, it appears that more effort is required in order to access the untapped potential of biocatalysis to enable the robust production of therapeutically superior constructs.

Keywords: biocatalysis, glycan, glycosylation, remodeling, glycosynthase, glycoform

INTRODUCTION

Monoclonal antibodies (mAbs) are established pharmaceutical modalities with rapidly expanding application in multiple therapeutic areas (Lin et al., 2015; Seeberger and Cummings, 2017; Li et al., 2020). In 2019, six out of the ten best-selling drugs world-wide were mAbs, treating macular degeneration, autoimmune conditions, and cancer (Urquhart, 2020). mAbs possess a conserved N-glycosylation site at Asparagine 297 (Asn297) in their crystallizable fragment (Fc), with its carbohydrate (glycan) identity dictating Fcγ-receptor (FcγR)-mediated pro- and anti-inflammatory activity and mAb stability (Reusch and Tejada, 2015). This N-glycosylation site is considered a critical quality attribute for mAbs that depend on Fc-mediated effector functions (Reason et al., 2014; Reusch and Tejada, 2015); its profound impact on mAb-dependent cell-mediated cytotoxicity (ADCC) and mAb-mediated inflammation has been studied in-depth (Batra and Rathore, 2016; Mimura et al., 2018). Changes in the available glycoforms (i.e. mAbs with identical protein component, but different Asn297 glycan composition) in therapeutic formulations can also affect the pharmacokinetics of mAbs, as exemplified in the C-type lectin clearance mechanism which is triggered by hypermannosylation (Goetze et al., 2011; Liu et al., 2013; Liu, 2015). Glycans on
natural human antibodies are usually of the bi-antennary complex type (Figure 1). Reliable production of targeted homogenous glycoforms is thus of pivotal importance for consistent, optimal therapeutic performance and improved pharmacokinetic profile of such drugs (Jefferis, 2009).

While mammalian systems like Chinese hamster ovary (CHO) and mouse myeloma (NS0, SP2/0) cells are the traditional gold standard for recombinant mAb production, these cell lines produce highly heterogeneous glycoproteins, reviewed in the literature (Batra and Rathore, 2016; Liu et al., 2016; Mastrangeli et al., 2019). Briefly, during incubation glycosylation is affected by changes in pH, availability of precursors, nutrients, growth factors and hormones; in subsequent extraction, glycosidases that are released by dead cells can catalyze partial to full degradation of the therapeutics’ glycan component in the culture medium. These processes result in the presence of more than 70 N-glycoforms identified in eight commercial therapeutic mAb formulations (Rosati et al., 2013; Song et al., 2014).

Therapeutics with homogenous glycoprofiles can be produced via total synthesis of the protein and glycan components and subsequent conjugation, utilizing mild chemo-selective ligation methods such as native chemical ligation and auxiliary-assisted ligation (Dawson et al., 1994; Dawson and Kent, 2000; Muir, 2003; Brik et al., 2006; Liu et al., 2006; Unverzagt and Kajihara, 2013). Despite the commendable progress in total synthetic approaches, the significant decrease in efficiency for proteins with over 50 residues limits the applicability in large-scale therapeutic manufacturing (Fernández-Tejada et al., 2015). Another approach to humanizing and homogenizing the protein glycoprofile is to extensively engineer the in vivo glycosylation pathways of the expression systems, such as in yeast, plant or mammalian cell lines, in order to access a restricted range of glycan types (Wang et al., 2019). Notable technologies in yeast and mammalian cells lines are summarized in Table 1, with similar developments underway in plant cell lines (Fischer et al., 2018; Montero-Morales and Steinkellner, 2018). However, in vivo glycoengineering usually does not lead to a completely homogeneous targeted glycoform – for example, the GlycoFi technology produces >90% homogenous glycoproteins with humanized complex N-glycans (Beck et al., 2010).

In vitro chemoenzymatic glycoengineering technologies have emerged as a way to circumvent the primary limitation of in vivo engineering, namely the requirement for divergent optimization of expression systems for each particular protein therapeutic and respective glycan type (via extensive gene knock-out or knock-in of specific glycosyltransferases) (Tang et al., 2017). Chemoenzymatic glycoengineering is a two-step process, whereby the native heterogeneous glycans are trimmed off to a single GlcNAc/Fuc-α-(1,6)-GlcNAc unit using wild-type endo-N-acetylgalactosaminidases (ENGases) (Fairbanks, 2017), with subsequent biocatalytic en bloc homogenous glycosylation (Figure 2A) (Chao et al., 2020). The ENGases (glycosyl hydrolase families GH85 and GH18) selectively cleave the diacetylchitobiose core [GlcNAc-β-(1,4)-GlcNAc] of N-linked glycans between the two GlcNAc residues (Maley et al., 1989; Karamanos et al., 1995) via a substrate-assisted mechanism which proceeds through an oxazolinium ion intermediate (Figure 2B) (Fujita et al., 2001; Umekawa et al., 2010). The (-1) 2-acetamido group of the substrate acts as a putative nucleophile, while the enzyme provides general acid/base catalysis and confers proper substrate orientation through the action of a pair of catalytic residues.

When the concept was originally introduced, the second step was to be catalyzed by glycosyltransferases (Witte et al., 1997), or by stimulating the transglycosylation activity possessed by some wild-type ENGases (Vic et al., 1996; Vetere et al., 2000; Balogh et al., 2004; Rising et al., 2006; Heidecke et al., 2008; Rising et al., 2008; Umekawa et al., 2008; Wei et al., 2008; Parsons et al., 2009). Following their construction in 1998 (Mackenzie et al., 1998),
glycosynthases overtook as the preferred catalyst. Prevention of oxazolinium ion formation in engineered ENGase-based glycosynthases can be obtained by two mutagenesis strategies, with the resulting mutants successfully processing externally supplied, pre-formed oxazolines as donors (Figure 2C). The more common and reliable strategy relies on mutation of the functionally equivalent Asn (GH85 family)/Asp (GH18 family) residues, responsible for correct substrate orientation, to a catalytically inert counterpart (like Ala) (Umekawa et al., 2008). The second approach, which employs mutation of the general acid-base catalytic residue, has successfully generated only one synthetically competent enzyme (Endo-A E173Q/H glycosynthase from Arthrobacter protophormiae), with non-performance for other ENGases (namely Endo-M from Mucor hiemalis) (Umekawa et al., 2010; Wang et al., 2019). The general inability of glycosynthases to re-hydrolyze the synthetic product in an aqueous environment leads to significantly improved yields compared to the use of wild-type glycosidases. They also have a more relaxed substrate specificity compared to glycosyltransferases and utilize easily accessible and less expensive sugar donors (Tang et al., 2017).

Chemoenzymatic glycoengineering affords homogenous glycoforms in high yields and in a chemo-, regio- and stereo-specific manner, which are all crucial in large-scale therapeutic production (Trincone and Giordano, 2006; Fairbanks, 2019). Reactions proceed in water under mild conditions, offering an attractive sustainable alternative to traditional organic synthesis. Multiple studies have demonstrated the utility of the glycosidase-glycosynthase cascade in producing homogenized constructs of commercially available mAb modalities, which possess enhanced

| Table 1 | Technologies for in vivo glycoengineering of yeast and mammalian protein expression systems. |
|---------|-----------------------------------------------------------------------------------------------|
| Company/Researcher | Technology | Engineered production system | Key features | Utilized on | References |
| VTU/RCT | GlycoSwitch | Pichia pastoris (Yeast) | 1) Prevent product hypermannosylation through disturbing the endogenous OCH1 gene coding for α-(1,6)-mannosyltransferase 2) Introduce heterologous glycosyltransferases to extend to target glycan | GM-CSF, CH2, IL22 Domain, IL10, IFNβ, Transferrin | Jacobs et al. (2009); Laukens et al. (2015) |
| GlycoFi Inc./Merck (Closed in 2016) | GlycoFi | Pichia pastoris (Yeast) | 1) Prevent product hypermannosylation via knock-out of 4 genes 2) Introduce up to 14 heterologous glycosylation genes | EPO | Beck et al. (2010) |
| Glycode | GlycodExpress (WO/2008/095,797) | Saccharomyces cerevisiae (Yeast) | 1) Prevent product hypermannosylation via knock-out of host OCH1 and MNN1 genes (+potentially additional mannosyltransferases) 2) Introduce heterologous glycol-enzyme active domains fused to yeast localization domains 3) Introduce novel metabolic pathways to produce nucleotide-sugar donors absent in yeast, such as GDP-fucose and CMP-sialic acid | EPO | Bonnet et al. (2012); Arico et al. (2013) |
| Glycotope | GlycoExpress (now used by Fionibi) | Human cell lines | Set of cell lines with specific capabilities such as: 1) mAbExpress® - high sialylation and core-fucosylation 2) mAbExpress® - high sialylation without core-fucosylation 3) SialoMax® - high sialylation and high core-fucosylation | EGFR, HER2 | Baumeister and Goeltz, (2010); Lugovsky et al. (2012); FioniBio, (2021) |
| GlycoDelete | HEK293 | | 1) Inactivate the GnT1 glycosyltransferase, encoded by MGAT7 2) Goji-targeted expression of an endo-β-N-acetylglucosaminidase (Endo-T) from fungus Hypocrea jecorina 3) Introduce a galactosyltransferase and sialyltransferase | GM-CSF, anti-CD20 | Meuris et al. (2014) |
| Kyowa Hakko Kirin (JP) Lonza (United Kingdom) | POTELLIGENT | CHO (Hamster) | Knock-out endogenous α-(1,6)-fucosyltransferase FUT8 to create 100% fucose-free mAbs | CCR4, CD98, GM2, IL5 | Yamane-Ohnuki et al. (2004) |
| Roche-Glycart | GlycoMAb | CHO (Hamster) | Overexpress heterologous β-(1,4)-N-acetylglucosaminyltransferase III (GnT-III) in antibody-producing cells | CD20, EGFR, HER2, HER3 | Sehn et al. (2012) |

Frontiers in Catalysis | www.frontiersin.org February 2022 | Volume 1 | Article 810779
activity and targeted properties (Supplementary Table S1). An extensive review of glycoprotein modification via chemoenzymatic methods by Li and Wang highlights the development of the technique to-date and further examples of its applicability (Li and Wang, 2018).

However, the technique has remained largely limited to preparative scale despite claims that it provides the optimal route towards homogenous N-glycosylated mAbs (Tomabechi et al., 2013; Lin et al., 2015), and no analysis of its applicability to industrial gram-scale therapeutic production is available. This review addresses this gap, identifying the challenges and potential solutions for large-scale implementation, with the goal of enhancing current therapeutic formulations. It considers the required components for chemoenzymatic glycoengineering: wild-type glycosidase with appropriate trimming specificity, activated extended glycan donor, glycosynthase with selected donor and acceptor substrate scope, and how these can be accessed selectively and in high yields to design an efficient manufacturing process.

ACCESSING ACTIVATED GLYCAN DONORS

There are three key steps when considering the required glycan donors for large-scale therapeutics with homogeneous glycoprofile: availability of the pure glycans in gram quantities, an efficient chemical activation method to produce suitable glycosynthase substrates, and selective and high-yielding protein glycosylation. All three aspects have been extensively developed for N-glycosylation. For implementation into therapeutic manufacturing, the entirety of the process must comply with therapeutic manufacturing standards and be sustainable and cost-effective.

Production of Pure N-Glycans for mAb Remodeling

Gram quantities of pure N-glycans can be accessed either through total chemical synthesis or via enzymatic modification of naturally available oligosaccharide precursors (Fairbanks, 2018; Chao et al., 2020). In total chemical synthesis, two major approaches have been predominantly applied: the epimerization approach and the Crich direct β-mannosylation, reviewed by Fairbanks (Fairbanks, 2018). Total chemical synthesis provides the advantage to access asymmetric glycans and add selective unnatural tags as handles for further chemical transformation (Lin et al., 2015). However, it involves multiple steps, complex orthogonal protecting group strategies, and heavy organic solvent use, which altogether have a negative impact on the process sustainability.
Complex N-glycans can also be isolated from natural precursors, such as sialylglycopeptide (SGP) 3 (Figure 3A). An optimized procedure for the production of SGP from dried egg yolk powder (as opposed to entire eggs) yields ≈0.8 mg of SGP per 1 g of egg yolk powder (Liu et al., 2017). The glycan from SGP can be truncated in situ with a mix of specific exo-glycosidases (like sialidase, β-(1,4)-galactosidase, etc.) to its desired composition; it can then be directly released from the peptide component via enzymatic cleavage catalyzed by wild-type Endo-M (Huang et al., 2009; Sun et al., 2014; Lin et al., 2015), or it can be divergently chemically functionalized for further modifications prior to Endo-M release, making it a versatile starting material for glycan isolation (Tang et al., 2016). The works by Kajihara, and more recently Boons, constitute further advances, allowing the production of truncated or tri- and tetra-antennary complex N-glycans (symmetrical or asymmetrical), which are otherwise inaccessible (especially at a large scale) via total synthetic approaches, from SGP (Maki et al., 2016; Liu et al., 2019).

SGP can be easily separated from its readily available precursor, with the caveat of incomplete homogeneity of the isolated SGP, which contains ≈10% impurities as species 4-6 (Figure 3C) (Liu et al., 2017). Impurity 6 is of little concern as the peptide component of SGP is cleaved off regardless of the additional hexose moiety. Structures 4 and 5, however, may be relevant if the targeted glycan is of the complex bi-antennary type, in which case SGP needs to be further purified. Using preparative hydrophilic interaction chromatography (HiLiC), the authors obtained homogenous SGP 3 in gram quantities, making this purification feasible for accessing pure N-glycans as part of a large-scale chemoenzymatic glycoengineering technology, albeit not very efficient. Whilst accessing SGP from egg-yolk may be cost-effective, its sustainability is questionable: the Process Mass Intensity (PMI), one of the standard green chemistry metrics, is bound to be very poor, due to the very low abundance of SGP within the egg yolk powder and the enormous amounts of waste associated, represented by a PMI contribution of 1,250 by the starting material alone.
Conversely, high-mannose type N-glycans can be isolated from soybean agglutinin, which is prepared from soybean flour (Wang et al., 2004). Sequential digestion with Pronase and Endo-A, and subsequent chromatographic purification affords homogenous Man$_9$GlcNAc glycans for further activation. Glycans with lower level of mannosylation (Man$_5$- and Man$_6$GlcNAc) were prepared by the same methodology from chicken ovalbumin.

In many ways, the approach to obtain pure glycans resembles that for many natural products: in the early stages of the demand, there is a competition between extraction from natural sources and chemical total synthesis. Isolation from natural sources - normally by-products of the agricultural industry - can be very cost-effective because of the extremely low cost of the natural source, but the low content of the desired compounds make the process very wasteful and historically, if the demand increases, eventually it cannot be sustained by extraction alone. On the other hand, chemical synthesis begins its journey with a much less efficient process but strives to incrementally improve efficiency and diversity of products, allowing researchers to tap into the therapeutic potential of unnatural glycan structures.

However, one can envision that the true long-term solution to the supply of pure glycans will come from synthetic biology, where a whole-cell microorganism will be engineered to produce the desired compound from cheap agricultural waste in much higher yields and homogeneity than those naturally occurring in egg yolk or soybean flour. A similar path was followed for insulin manufacturing, which moved from pancreatic extraction to recombinant production in either *Escherichia coli* or *Saccharomyces cerevisiae* (Walsh, 2005; Baeshen et al., 2014). Subsequent chemical modification of the biotechnologically obtained glycan may offer access to semisynthetic glycans with unique chemical handles, in analogy to current approaches for accessing semisynthetic penicillins (Deng et al., 2016).

**The Oxazoline Issue**

The glycosylation step via glycosynthase catalysis relies on chemical activation of the donor glycans into oxazolines, which mimic the enzyme-activated intermediate. Initially, oxazoline formation was carried out on per-acetylated glycans in dichloroethane with bromotrimethylsiline (TMSBr) and BF$_3$Et$_2$O in the presence of 2,4,6-collidine; the activated species in the reaction mixture leads to non-enzymatic, hydrolytic conversion imposes the use of the corresponding catalytic intermediate, the highly activated oxazoline moiety is readily hydrolyzed by the water molecules in the enzymatic active site (Umekawa et al., 2008). While the hydrolyzed free glycan can be recovered from the reaction and re-formed into the oxazoline (Wang and Amin, 2014), this unproductive hydrolytic conversion imposes the use of the corresponding donor in excess to achieve competitive glycosylation yields. The excess of oxazoline required increases significantly for folded protein targets and mAbs, due to entropy limitations and reduced access to the target peptide site; even in conditions with high oxazoline excess, glycosylation of more than a single site may not proceed to completion (Wang et al., 2020). In addition, the high concentration of the reactive oxazoline species in the reaction mixture leads to non-enzymatic, chemical “glycation” of the mAb target, first reported by Davis (Parsons et al., 2016). Further investigation showed that when GlcNAc-oxazoline was added to the model peptide Ac-L-Ala-L-Lys-L-Ala-NH$_2$ under traditional glycosylation conditions (50 mM phosphate buffer of pH 8.0) but in the absence of a glycosynthase, there was evident chemical ligation of the glycan chain onto the single Lys residue (Figure 4) (Wang et al., 2016). Incubation of up to 15 h resulted in 90% yield of the glycated side-product. As expected, such glycation was not observed in the control reaction with GlcNAc instead of GlcNAc-oxazoline, confirming that it is the highly activated oxazoline moiety which drives Lys-glycan association.

Any solution for large-scale oxazoline use in chemoenzymatic glycoengineering must address all these issues simultaneously, optimizing selective glycosylation yields and minimizing...
unproductive hydrolysis or side glycation. Reduction of unproductive oxazoline hydrolysis has been attempted via the inclusion of organic co-solvents such as dimethylsulfoxide (DMSO) or acetone, which decrease effective water concentration; however, they also negatively impact synthetic reaction rates or enzyme stability (Heidecke et al., 2009). Lowering the pH of the reaction buffer to 6.5 reduces non-enzymatic glycan ligation to Lys residues, but it also lowers targeted glycosylation efficiency due to the instability of the oxazoline moiety at acidic pH (Manabe et al., 2019). Successful suppression of side-reactions without negative impact on protein glycosylation yields was achieved with the following conditions: 10% w/w glycosynthase loading, and step-wise oxazoline addition (Parsons et al., 2016; Manabe et al., 2019). The required strict control over peak oxazoline concentration, alongside the high enzymatic loading, can be challenging for industrial-scale application.

We propose that the ideal solution to this issue could be achieved in the future by a combination of enzyme and process engineering: in absence of glycosynthase, the activated oxazoline is stable to chemical hydrolysis under the typical assay conditions. Therefore, enzyme engineering could be aimed at reducing the enzyme-catalyzed hydrolysis of the oxazoline, favoring the glycosynthase reaction over the unproductive hydrolysis. This improvement should reduce the overall excess of oxazoline required. Conversely, the critical oxazoline concentration at process scale can be controlled to maximize the productive glycosynthase reaction over the undesired competing oxazoline hydrolysis and Lys glycation. This can be achieved by carefully designed engineering solutions, such as fed-batch or continuous reactor with appropriate process analytics; flow biocatalysis has also emerged as an interesting technology to operate at controlled concentration of reactive chemicals (amongst other benefits) and we envision it will become prominent in the future of chemoenzymatic glycosylation (Britton et al., 2018). An other complementary approach to manage the oxazoline problem is in situ substrate formation, as described below.

**Circumventing Oxazoline Isolation: One-Pot Glycosylation**

A novel approach to resolving the issues associated with excess oxazoline is utilizing a one-pot glycosylation strategy that confers activated species formation in situ; this has the added benefit of bypassing oxazoline purification. The strategy was initially developed by the Huang group, which converted in situ the glycan from SGP to the corresponding oxazoline in order to homogenously glycosylate Fuc-α-(1,6)-GlcNAc-Fc trastuzumab with Endo-S D233Q glycosynthase (from Streptococcus pyogenes) (Figure 5A) (Tang et al., 2016). As discussed, Endo-M can be combined with additional exo-glycosidases in order to trim the glycan further to the desired composition prior to acceptor addition. Minimizing the peak oxazoline concentration and glycosylation incubation times reduces unproductive hydrolysis and avoids non-enzymatic glycation. The authors report that the activity of the glycosynthase Endo-S D233Q is not affected by the presence of the 1,3-dimethyl-2-imidazolidin-2-one (DMI) hydrolysate of DMC (Tang et al., 2016), which is in disagreement with Shoda’s previous findings that DMI has a notable inhibitory effect on enzymatic catalysts (Noguchi et al., 2012).

A step further in one-pot glycosylation strategies is circumventing chemically-induced oxazoline formation altogether: the Hasegawa group reported a successful transfer of the sialylated bi-antennary complex type glycan moiety from SGP to Fuc-α-(1,6)-GlcNAc-Fc trastuzumab with Endo-S D233Q glycosynthase via the complementary activity of two glycosynthases (Figure 5B) (Iwamoto et al., 2018). One glycosynthase (Endo-M N175Q) converts the glycan from SGP to an active intermediate (not yet identified), while the second glycosynthase (derived from Endo-M...
S) catalyzes the selective glycosylation of the mAb with this activated SGP-derived glycan species. The glycosylation efficiency was excellent, at 95% with Endo-S D233Q, but could be increased even further to 97% via utilizing either the double mutant Endo-S D233Q/E350Q or the glycan-Asn as a starting material (instead of full-length SGP peptide). While the precise mechanism of the transformation is unclear, it implies some level of retained hydrolytic capability by Endo-M N175Q which enables glycan release from the peptide component of SGP.

Similar capability to process full-length SGP in mAb glycosylation was observed with the N180H glycosynthase variant of Endo-CC from Coprinopsis cinerea (Figure 5C) (Manabe et al., 2018). Core-fucose deficient GlcNAc-Fc anti-CCR4 mAb was deglycosylated by wild-type Endo-S, and then re-engineered with homogenous sialylated bi-antennary complex type glycosylation pattern in 85% yield via one-pot glycosylation strategy with Endo-CC N180H and SGP. One significant drawback of both these processes is that SGP is required in hundreds of molar equivalents excess to drive high yields of mAb remodeling, significantly impacting the efficiency and sustainability (Iwamoto et al., 2018; Manabe et al., 2018).

On paper, one-pot glycosylation without chemical oxazoline formation looks like a simplified process with minimized side reactions, but it presently requires significant further optimization in order to become an industrially viable technology. Given that the process envisions the use of two separate glycosynthases, potentially both capable of catalyzing every reaction in the process (including unproductive hydrolyses and transglycosylation) it is speculative whether it will be possible to fine tune both catalyst by enzyme engineering to selectively enable only the desired step and avoid any side reactions.

INTEGRATING CHEMOENZYMATIC GLYCOENGINEERING IN CURRENT GLYCOPROTEIN THERAPEUTIC PRODUCTION

Incorporating chemoenzymatic glycoengineering in the production of glycoengineered mAb therapeutics may appear challenging due to the need to accommodate multiple enzymes and additional reaction and purification steps into the overall process. The task is further complicated by the increasing choice of both wild-type and engineered enzymes. However, through careful analysis of the available enzymatic panels and strategies, the technology can be streamlined to access optimal glycoforms with minimal divergence.

Target-Based Selection of Enzymes

Successful implementation of chemoenzymatic glycoengineering relies upon the selection of wild-type glycosidase and engineered glycosynthase enzymes with the appropriate specificity to match the synthetic target. The major advance in mAb glycoengineering...
came with the discovery of Endo-S, which hydrolyses solely the core complex glycans on humanized, fully folded IgG mAbs, with marginal activity on hybrid type and high-mannose type glycans (Fairbanks, 2017). It is traditionally used across the literature for deglycosylation, but also recognizes the according glycan donor. The logical approach to this heterogeneity is to investigate and characterize a broader spectrum of glycosynthases, both by expanding the spectrum of wild-type enzymes and the number of engineered mutants for a given enzyme. The ultimate goal is to provide a number of well-characterized catalysts, ranging from generally applicable to specifically tailored, to cover the broadest possible panel of donors and acceptors.

Indeed, Endo-S2 mutants are emerging as the optimal choice for mAb homogenous glycosylation due to their broad donor and acceptor scopes, which surpass the capabilities of Endo-S glycosynthases. Endo-S2 D184M can glycosylate both core-fucosylated and non-fucosylated acceptors with all major types of N-glycans (Li et al., 2016). Further mutagenesis studies resulted in a broad panel of glycosylase-like Endo-S2 mutants (T138D, T138E, T138F, T138H, T138K, T138L, T138M, T138N, T138Q, T138R, T138V, T138W, T138W, D182Q, D226Q, T227Q, and T228Q), which afford access to an expanded glycan donor set, including tri-antennary variants (Shivatare et al., 2018). Ability to utilize multi-antennary glycan donors is a sought-after improvement, as such donors are generally not accepted by the ENGases; a notable exception is Endo-F3 (from Flavobacterium meningosepticum) mutants D165A and D165Q, whose activity is however limited to non-fucosylated IgGs (Giddens et al., 2016). The use of Endo-S2 mutants in glycoprotein remodeling was patented by CHO Pharma Inc., a Taiwan-based start-up company, as part of their proprietary technology for mAb glycoprotein homogenization (Lin et al., 2018).

Immobilization Strategies

A caveat to in vitro chemoenzymatic glycoengineering is that the deglycosylated glycotherapeutic intermediate must be meticulously purified from the wild-type glycosidase used in heterogenous glycan trimming, since any residual contamination will result in re-hydrolysis of the final product generated in Step 2 (Li et al., 2018). Separating the products from the unreacted starting material and wild-type glycosidase is generally a difficult task, but is more readily achieved in the case of mAbs, where protein A column can be utilized for affinity chromatography (Hober et al., 2007). If the deglycosylation step is performed in vitro, easy separation of the glycosidase from the target protein can be readily achieved through glycosidase immobilization on solid support. Immobilizing both enzymes in the two-step glycoengineering cascade allows glycoprotein remodeling without intermediate purification, which reduces solvent usage, allows catalyst recycling, and simplifies product isolation compared to solution-phase reactions. It is also compatible with advantageous flow reactor designs.

Recently, there have been two significant reports of glycosidase/glycosynthase immobilization. In the first example, wild-type Endo-S2 and its D184M mutant were covalently immobilized on functionalized agarose (Figure 6A) (Li et al., 2018). The enzymes were successfully applied to the homogenization of commercial trastuzumab with bi-antennary complex type glycans. Following fast deglycosylation with wild-type Endo-S2, trastuzumab was eluted from the agarose-loaded column, alongside the released free N-glycans. The eluent was directly applied onto the second, glycosynthase-loaded column, together with the corresponding oxazoline, and homogenously glycosylated trastuzumab was obtained after 1–2 h incubation at ambient temperature.

It was reported that immobilized Endo-S2 could be re-used for several runs without notable loss of activity, but there was lack of specific data on the recycling capability and enzymatic stability over time (Li et al., 2018). A potential drawback of this strategy is that the pre-purification of the glycosynthase for trans-glutaminase-mediated immobilization on the support limits the scale up of this specific strategy. A second-generation
Immobilization strategy resolved this limitation by fusing Endo-S and its D233A and D233Q mutants to a cellulose-binding domain (CBD), which acts as an affinity tag and affords one-step purification and immobilization on cellulose, with respective loading efficiency of 86, 81 and 90% under optimal conditions (Figure 6B) (Zhao et al., 2019). Addressing the previous gap in data about the properties of the immobilized enzymes, this study concluded that Endo-S and its mutants could be stored at 4°C for over 30 days and re-used for more than five catalytic cycles without significant loss of activity. Alongside the demonstrated efficiency of commercial rituximab deglycosylation (1 h at 37°C under constant shaking) and subsequent re-glycosylation with azide-tagged oxazoline (1.5 h at 30°C, quantitative glycosylation of 5 mg/ml mAb), the proven stability and recyclability of the immobilized enzyme suggest that solid-phase glycan remodeling via CBD-immobilized enzymes could be an industrially viable process for gram-scale modifications, with lower additional costs over its solution-phase counterpart.

Even if the specific support and immobilization strategy may ultimately prove not convenient, enzyme immobilization is a well-established field with numerous cost-effective and precedent strategies for use at process scale, and finding a suitable strategy for glycosynthase immobilization should not prove difficult: plenty of fast and effective immobilization systems exist (e.g., the simple His-tag/Ni column), which can afford purification/enrichment and immobilization of a desired enzymatic catalyst in a single step (Tischer and Kasche, 1999; Zhou et al., 2017). A great benefit to the development and adoption of chemoenzymatic approaches to glycan remodeling will be the commercial availability of the broad-spectrum enzyme panel envisioned in Target-based selection of enzymes in an immobilized and ready-to-screen format.

The Universal Glycan

The diversity of available glycan structures may pose a significant barrier to the viable industrial production of homogenously glycosylated mAbs, as distinct synthetic protocols would be required to access such vast array of donors. Although a long-term synthetic solution may be provided by synthetic biology and an array of glycan-producing engineered microorganisms, reducing the number of glycans used would simplify the task both in the immediate and long-term future. A potential solution would be to streamline existing structure-activity relationship for specific glycan features into a small set of defined structures which afford improvement of the targeted properties for a therapeutic class (anti-inflammatory, cytotoxic, etc.), allowing batch glycan synthesis. The term “universal glycan” was coined by Wong et al. to describe the non-fucosylated, bi-antennary sialylated complex type glycan which, upon homogenous addition to anti-cancer mAbs, proved optimal for enhancing effector functions (Lin et al., 2015). Homogenization of rituximab with this universal glycan stimulated activity on generic rituximab-resistant cell lines, and both remodeled rituximab and trastuzumab demonstrated improved binding to FcγIIIaR and enhanced ADCC, primarily due to the removal of core-fucose (Shields et al., 2002; Nakamura et al., 2003). Furthermore, the incorporated terminal α-(2,6)-sialylation confers anti-inflammatory activity to mAbs (Anthony et al., 2008).

Three additional mAbs of the IgG type, which target the surface glycoprotein of Ebola virus, were engineered with such
homogenous, non-fucosylated, sialylated complex-type-Fc glycoprofile (Chen et al., 2017). When assessing their ADCC activity in comparison to the parent, heterogenous mAbs, the authors observed “gain-of-function” for two of the engineered variants. The parent counterparts showed no measurable ADCC activity even at concentrations as high as 40 μg/ml, which suggests that they exert their therapeutic function via neutralizing the virus itself. However, the according engineered variants demonstrated significant ADCC, with EC_{50} values of 0.219 μg/ml and 0.387 μg/ml. These striking results confirm that careful control over a therapeutic’s glycoprofile can introduce and enhance functionality, with the non-fucosylated bi-antennary sialylated complex type glycoform appearing as the optimal choice for Fc-mediated effector function improvement.

**CLINICAL RELEVANCE OF CHEMOENZYMATIC GLYCOENGINEERING**

Chemoenzymatic glycoengineering is a readily applicable technique for accessing glycovariants that may be challenging to obtain through traditional chemical synthesis. These glycoforms can have very dramatic impact on the pharmacokinetics, bioavailability, and efficacy of the therapeutic protein. For example, Endo-A N171A can successfully glycosylate therapeutics with high-mannose type oxazolines containing terminal mannose-6-phosphate moieties, thus enabling selective drug targeting to the lysosome, which is essential in enzyme replacement therapies for lysosomal storage disorders (Priyanka et al., 2016; Yamaguchi et al., 2016). Furthermore, through careful control and homogenization of glycosylation patterns, one can access improved therapeutic constructs with novel and enticing activities, capable of addressing efficacy challenges in minor patient populations.

**mAb “Biobetters”**

There is now prevailing evidence that Fc-glycosylation patterns have notable impact on mAb interactions with immune cells, affecting ADCC and antibody-mediated inflammation. Removal of core fucose has been shown to significantly improve ADCC through enhancing mAb affinity for the FcγIIa receptor (Shields et al., 2002; Nakamura et al., 2003). This is of particular significance for patients with the low-affinity FcγRIIIa-F158 allelic polymorphism and provides a sought-after improvement of anti-cancer activity in these cases (Huang et al., 2012). Homogenous afsucosylated glycoforms of rituximab, accessed through chemoenzymatic glycoengineering, demonstrated much improved binding to both forms of the FcγIIa receptor when compared to their commercially available heterogeneous counterpart, that includes primarily fucosylated motifs (Huang et al., 2012; Li et al., 2017). Similarly, the terminal α-(2,6)-sialylated glycoforms are known to confer the anti-inflammatory effect of the widely used intravenous immunoglobulin G (IVIG); it is proposed that one of the reasons for the high doses required to elicit therapeutic effect is that the active glycoform is only a minor component of the glycoprofile in commercially available preparations (Kaneko et al., 2006; Anthony et al., 2008).

Chemoenzymatic glycoengineering provides a viable strategy for accessing mAb constructs with consistent, enhanced targeted activity. Up to date, only three mAb therapeutics approved by the U.S. Food and Drug Administration (FDA), have been subjected to some form of glycoengineering: obinutuzumab (GA101 or Gazyva®) was first in 2013, followed by mogamulizumab (POTELIGEO®) and benralizumab (MEDI-563, Fasenra™) in 2017 (Lin et al., 2015; Pereira et al., 2018). All three drugs are produced in glyco-engineered CHO cell lines, which leads to enrichment of specific glycoforms without full homogeneity. CHO Pharma Inc. is the first pharmaceutical company to develop fully homogenous “biobetter” versions of commercially available antibodies through their propriety glycan engineering platform (Lin et al., 2018). The company patented the term “glycoatibodies” to describe antibody therapeutics with homogenous Fc-region glycoform, constructed through chemoenzymatic glycoengineering of the Fc region (Wong et al., 2015). In March 2018, its first ever anti-CD20 glycoatibody entered Phase I clinical trial (Trial ID: NCT03221348) for refractory or relapsed follicular lymphoma, evidencing the applicability of glycoprofile homogenization to industrial formulations (2017).

**Unnatural Glycosylation and Antibody-Drug Conjugates (ADCs)**

Through the enzymatic addition of unnatural glycans with a precise number of chemical handles for cargo attachment, one can access ADCs with defined and tunable drug to antibody ratio (DAR) (OY, 2018). Conjugation of payloads to the Fc N-glycan of the antibody component provides an optimal strategy for ADC creation, as the glycan position is far away from the antigen-binding region, ensuring that the cargo does not interfere with antigen recognition (Manabe et al., 2019). Primarily, the glycosynthase mutants of Endo-S have catalyzed the transfer of chemically modified glycans to deglycosylated mAbs, facilitating further payload conjugation through click-chemistry. Transfer of an azide-tagged glycan onto trastuzumab, catalyzed by Endo-S D233Q, allowed for subsequent biorthogonal conjugation to introduce the cytotoxic agent monomethyl auristatin E (MMAE), creating a glycosite-specific antibody-drug conjugate with doubly enhanced therapeutic activity (Manabe et al., 2019). Each step of the ADC preparation produced a single UPLC product peak, in contrast to the traditionally employed chemical conjugation between the maleimide and sulfhydryl group which results in multiple impurity peaks in UPLC analysis.

Huang et al. further applied their one-pot, in-situ oxazoline formation technology to obtain homogenously glycosylated variants of trastuzumab with azide or alkyne chemical handles (Tang et al., 2016). The chemical handles on the homogenized mAb enabled ADC formation via strain-promoted copper-free click chemistry with a dibenzocyclooctyne (DBCO)-conjugated payload (cytotoxic or reporter) like DM1, MMAE or the fluorescent tag Cy5. The advantage of site-specific payload
conjugation to the glycan component was evidenced through the antigen-binding activity (K_d values) of commercial trastuzumab, glycoside-labelled Cy5-trastuzumab and random-labelled Cy5-trastuzumab, which were measured as 1.2, 3.5, and 24 μg ml^{-1} respectively. Glycoside-specific Cy5 conjugation resulted in significantly higher antigen-binding activity, demonstrating that ADC formation through glycan homogenization avoids unwanted influences on the antigen-binding domain, which are common in random conjugation to Lys mAb residues.

**DISCUSSION**

Implementing chemoenzymatic glycoengineering to the large-scale glycan homogenization of commercially available glycotherapeutics is an exciting strategy towards the production of safer and improved therapies with enhanced targeted activity. However, there are several hurdles preventing the current application of such in vitro glycoengineering to large-scale therapeutic production. While there is clear evidence that single glycoforms of therapeutic proteins have not only higher batch-to-batch reproducibility, but also enhanced therapeutic properties from targeting to efficacy, their posttranslational engineering needs to meet the strict regulatory challenges of the industry. Therefore, the current industrial perspective is that it is still more costly to produce single glycoforms than it is to provide a defined, albeit heterogeneous, population of glycoforms which confers a suboptimal but reproducible therapeutic profile. The latter can be usually achieved by cell line engineering with contained investment and no impact on the mAb production process.

Further development is still necessary to make chemoenzymatic glycoengineering economically attractive: given that the glycoengineered mAb is the final drug substance, it is safe to assume that the glycoengineering step would need to be performed under GMP, which has a higher cost associated with manufacturing plant occupancy and also very strict characterization and quantification of impurities; to address the latter, both enzymes used in the glycoengineering cascades would have to be purified, which in itself is a high cost contributor. The significant portion of unproductive conversions during chemoenzymatic glycoengineering leads to poor atom economy and further decreases process sustainability. Furthermore, we require improved, sustainable and cost-effective methods for production of complex glycan donors on demand, ideally from agricultural waste.

Throughout this review, we have highlighted potential solutions to all of the outstanding barriers to the wider implementation of chemoenzymatic glycoengineering, which build on the tremendous scientific advances in enzyme engineering, synthetic biology, and process chemistry. In the first instance, a viable process for the homogenization of mAb N-glycProfiles would likely focus on optimization of only one enzyme (probably Endo-S2 due to its relaxed substrate specificity) acting on a single glycan donor set (the universal glycan), to alleviate the aforementioned difference in substrate scope and acceptance between enzymes (Heidecke et al., 2009). It would implement process solutions (such as enzyme immobilization and packed bed reactors) to comply with the regulatory framework in a cost-efficient manner, and it would address the issue of starting material (glycans) sustainable supply.

Ultimately, it will be the change in the regulatory landscape, spearheaded by the enhanced therapeutic activity and functionality of engineered glycoform, that will make the production of single glycoforms the norm in the industry. In this context, chemoenzymatic glycan remodeling, with all the improvements discussed and suggested within this review, will position itself as a strong enabling technology.

**AUTHOR CONTRIBUTIONS**

AI conducted the majority of reviewing of the literature. AI and FF prepared and wrote the manuscript. FF provided key opinions on the discussed industrial challenges. All authors reviewed the manuscript.

**FUNDING**

The publication of this work is part of a joint research project between the University of Edinburgh and AstraZeneca.

**ACKNOWLEDGMENTS**

We would like to acknowledge Prof Dominic Campopiano for his valuable inputs and Dr Nathaniel Gordon for his help with the lab work on the glycosidase and glycosynthase expression and his feedback during manuscript production.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fctls.2021.810779/full#supplementary-material

**REFERENCES**

Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., and Ravetch, J. V. (2008). Recapitulation of IVIG Anti-inflammatory Activity with a Recombinant IgG Fc. Science 320 (5874), 373–376. doi:10.1126/science.1154315
Balogh, T., Boross, L., and Kosáry, J. (2004). Novel Reaction Systems for the Synthesis of O-Glycosides by Enzymatic Reverse Hydrolysis. Tetrahedron 60, 679–682. doi:10.1016/j.tet.2003.10.098

Batra, J., and Rathore, A. S. (2016). Glycosylation of Monoclonal Antibody Products: Current Status and Future Prospects. Biotechnol. Prog. 32, 1091–1102. doi:10.1002/btp.2366

Baumeister, H., and Härter, M. (2010). Psychische Komorbidität bei muskuloskelettalen Erkrankungen. Bundesgesundheitsbl. 54, 52–58. doi:10.1007/s00103-010-1185-x

Beck, A., Cochet, O., and Wurich, T. (2010). GlycoFi’s Technology to Control the Glycosylation of Recombinant Therapeutic Proteins. Expert Opin. Drug Discov. 5 (1), 95–111. doi:10.1517/17464490903143504

Bennett, L., Yang, Q., Bergquist, B., Giddens, J., Ren, Z., Kommineni, V., et al. (2018). Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies. Int. J. Mol. Sci. 19 (2), 421. doi:10.3390/ijms19020421

Bonnet, C., Arico, C., Rigaud, C., Blandais, C., Chanteclaire, E., Tassy-Freches, E., Bennett, L., Yang, Q., Berquist, B., Giddens, J., Ren, Z., Kommineni, V., et al. (2018). “Glyco-engineering of Plant-Based Expression Systems,” in Advances in Glycobiotechnology. Editors E. Rapp and U. Reichl (Cham: Springer), 137–166. doi:10.1007/10_2018_76

Fujita, M., Shoda, S.-i., Haneda, K., Inazu, T., Takegawa, K., and Yamamoto, K. (2001). A Novel Disaccharide Substrate Having 1,2-oxaoline Moiety for Detection of Transglycosylating Activity of Endoglycosidases. Biochim. Biophys. Acta (BBA) - Gen. Subjects 1528, 9–14. doi:10.1016/s0304-4165(01)00164-7

Fyonibio (2021). GlycoExpress®(GEX®) [Online]. Available at: https://www.fyonibio.com/wp-content/uploads/2021/10/Flyer-Fyonibio-GlycoExpress-10-2021_web.pdf (Accessed October, , 2021).

Giddens, J. P., Lomino, J. V., Amin, M. N., and Wang, L.-X. (2016). Endo-F3 Glycosynthase Mutants Enable Chemoenzymatic Synthesis of Core-Fucosylated Triantennary Complex Type Glycopeptides and Glycoproteins. J. Biol. Chem. 291 (17), 9356–9370. doi:10.1074/jbc.m115.721597

Giddens, J. P., Lomino, J. V., DiLillo, D. J., Razvet, J. V., and Wang, L.-X. (2018). Site-selective Chemoenzymatic Glycoengineering of Fab and Fc Glycans of a Therapeutic Antibody. Nat. Prod. Sci. Acad. USA 115 (47), 12023–12027. doi:10.17813/nps18283311

Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., et al. (2011). High-mannose Glycans on the Fc Region of Therapeutic IgG Antibodies Increase Serum Clearance in Humans. Glycobiology 21 (7), 949–959. doi:10.1039/c0gc00279f

Heidcke, C. D., Ling, Z., Bruce, N. C., Moir, J. B. W., Parsons, T. B., and Fairbanks, A. J. (2008). Enhanced Glycosylation with Mutants of Endoheoxosaminidase A (Endo A). ChemBioChem 9 (13), 2045–2051. doi:10.1002/cbic.200800214

Hober, S., Noré, K., and Linhult, M. (2007). Protein A Chromatography for Antibody Purification. J. Chromatogr. B 848 (1), 40–47. doi:10.1016/j.jchromb.2006.09.030

Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., and Wang, L.-X. (2012). Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions. J. Am. Chem. Soc. 134 (29), 12308–12318. doi:10.1021/ja3051266

Huang, W., Li, C., Li, B., Umekawa, M., Yamamoto, K., Zhang, X., et al. (2009). Glycosynthases Enable a Highly Efficient Chemoenzymatic Synthesis of N-Glycoproteins Carrying Intact Natural N-Glycans. J. Am. Chem. Soc. 131 (6), 2214–2223. doi:10.1021/ja8074677

Iwamoto, M., Sekiguchi, Y., Nakamura, K., Kawaguchi, Y., Honda, T., and Hasegawa, J. (2018). Generation of Efficient Mutants of Endo-β-d-Glucosaminidases? GlycoSwitch Technology. Nat. Protoc. 4 (58), 58–70. doi:10.1038/nprot.2008.213

Jeffris, R. (2009). Glycosylation as a Strategy to Improve Antibody-Based Therapeutics. Nat. Rev. Drug Discov. 8 (3), 226–234. doi:10.1038/nrd2804

Tanaka, Y., Nimmerjahn, F., and Ravetch, J. V. (2006). Anti-inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation. Science 313 (5787), 670–673. doi:10.1126/science.1129594

Karamanos, Y., Bourgerie, S., Barreaud, J.-P., and Julien, R. (1995). Are There Biological Functions for Bacterial Endo-N-Acetyl-β-D-Manosidases? Microbiol. Rev. 59 (2), 437–443. doi:10.1128/MBR.59.2.437-443.1995

Ko, S.-H., Heidecke, C. D., Ling, Z., Bruce, N. C., Moir, J. B. W., and Parsons, T. B. (2008). Engineering the Cities of IgG-Active Fc Reagent (DMC) and Analogues for Biological Functions for Bacterial Endo-N-Acetyl-β-D-Glucosaminidase from Streptococcus Pyogenes. Infect. Immun. 80 (4), 1400–1407. doi:10.1128/IAI.00628-08

Ko, S.-H., Jefferis, R. (2009). Chemoenzymatic Synthesis of N-Glycosylated Human IgG Antibodies with Enhanced Serum Stability. J. Am. Chem. Soc. 131 (8), 2983–2984. doi:10.1021/ja8074677

Laukens, S., Jefferis, R., Van Buyten, S., Huygen, M., Geysens, P., Mertens, K., et al. (2009). Engineering Complex-type N-Glycosylation of Pichia pastoris Using GlycoSwitch Technology. Nat. Protoc. 4 (58), 58–70. doi:10.1038/nprot.2008.213

Li, C., Wang, L.-X. (2018). Chemoenzymatic Methods for the Synthesis of Glycopeptides. Pharm. Rev. 118 (17), 8359–8413. doi:10.1021/acs.chemrev.8b00238

Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., and Wang, L.-X. (2017). Modulating IgG Effector Function by Fc Glycan Engineering. Proc. Natl. Acad. Sci. USA 114 (3), 3485–3490. doi:10.1073/pnas.1702173114

Li, T., Li, C., Quan, D. N., Bentley, W. E., and Wang, L.-X. (2018). Site-specific Immobilization of Endoglycosidases for Streamlined Chemoenzymatic Glycan
Shivatre, S. S., Huang, L.-Y., Zeng, Y.-F., Liao, J.-Y., You, T.-H., Wang, S.-Y., et al. (2018). Development of Glycosynthases with Broad Glican Specificity for the Efficient Glyco-Remodeling of Antibodies. Chem. Commun. 54, 6161–6164. doi:10.1039/c8cc03384f

Sjögren, J., Struwe, W. B., Cosgrave, E. F., Rudd, P. M., Stervander, M., Allhorn, M., et al. (2013). EndoS2 Is a Unique and Conserved Enzyme of Serotype M49 Group A Streptococcus that Hydrolyses N-Linked Glycans on IgG and α1-acid Glycoprotein. Biochem. J. 455 (1), 107–118. doi:10.1042/BJ20130126

Sjögren, J., Cosgrave, E. F. J., Allhorn, M., Nordgren, M., BJörk, S., Olsson, F., et al. (2015). EndoS and EndoS2 Hydrolyze Fc-Glycans on Therapeutic Antibodies with Different Glycoform Selectivity and Can Be Used for Rapid Quantification of High-Mannose Glycans. Glycobiology 25, 1053–1063. doi:10.1093/glycob/cwv047

Song, T., Ozcan, S., Becker, A., and Lebrilla, C. B. (2014). In-depth Method for the Characterization of Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs. Anal. Chem. 86 (12), 5661–5666. doi:10.1021/ac50101t

Sun, B., Bao, W., Tian, X., Li, M., Liu, H., Dong, J., et al. (2014). A Simplified Procedure for Gram-Scale Production of Sialylglycopeptide (SGP) from Egg Yolks and Subsequent Semi-synthesis of Man3GlcNacOxazoline. Carbohydr. Res. 396, 62–69. doi:10.1016/j.carres.2014.07.013

Tang, F., Wang, L.-X., and Huang, W. (2017). Chemoenzymatic Synthesis of Glycoeengineered IgG Antibodies and Glycosite-specific Antibody-Drug Conjugates. Nat. Protoc. 12 (8), 1702–1721. doi:10.1038/nprot.2017.058

Tang, F., Yang, Y., Tang, Y., Yang, L., Sun, B., et al. (2016). One-pot N-Glycosylation Remodeling of IgG with Non-natural Sialylglycopeptides Enables Glycosite-specific and Dual-Payload Antibody-Drug Conjugates. Org. Biomol. Chem. 14, 9501–9518. doi:10.1039/c6ob01751g

Tischer, W., and Kasche, V. (1999). Immobilized Enzymes: Crystals or Carriers? Trends Biotechnol. 17 (8), 326–335. doi:10.1016/S0167-7799(99)01322-0

Tomabechi, Y., Krippner, G., Rendle, P. M., Squire, M. A., and Fairbanks, A. J. (2013). Glycosylation of Pramlintide: Synthetic Glycopeptides that Display In Vitro and In Vivo Activities as Amylin Receptor Agonists. Chem. Eur. J. 19 (45), 15084–15088. doi:10.1002/chem.201303030

Trincone, A., and Giordano, A. (2006). Glycosyl Hydrolases and Glycosyltransferases in the Synthesis of Oligosaccharides. Bioorg. Chem. 44, 4469–4479. doi:10.1016/j.bioorg.2006.10.007

Umekawa, M., Huang, W., Li, B., Fujita, K., Ashida, H., Wang, L.-X., et al. (2008). Mutants of Mucor Hiemalis Endo-β-N-Acetylgalcosaminidase Show Enhanced Transglycosylation and Glycosynthese-like Activities. J. Biol. Chem. 283, 4469–4479. doi:10.1074/jbc.m70737200

Umekawa, M., Li, C., Higashiyama, T., Huang, W., Ashida, H., Yamamoto, K., et al. (2010). Efficient Glycosylnystone Mutant Derived from Mucor Hiemalis Endo-β-N-Acetylgalosaminidase Capable of Transferring Oligosaccharides from Both Sugar Oxazoline and Natural N-Glycan. J. Biol. Chem. 285, 511–521. doi:10.1074/jbc.m109.059832

Unverzagt, C., and Kajihara, Y. (2013). Chemical Assembly of N-Glycoproteins: a Refined Toolbox to Address a Ubiquitous Posttranslational Modification. Chem. Soc. Rev. 42, 4048–4020. doi:10.1039/c3cs35485g

Urquhart, L. (2020). Top Companies and Drugs by Sales in 2019. Top Companies

Wang, N., Seko, A., Dukoku, S., Kanie, O., Takada, Y., and Ito, Y. (2016). Non-enzymatic Reaction of Glycosyl Oxazoline with Peptides. Carbohydr. Res. 436, 31–35. doi:10.1016/j.carres.2016.11.002

Wang, X., Ashhurst, A. S., Downman, L. J., Watson, E. E., Li, H. Y., Fairbanks, A. J., et al. (2020). Total Synthesis of Glycosylated Human Interferon-γ. Org. Lett. 22 (17), 6863–6867. doi:10.1021/acs.orglett.0c02401

Wei, Y., Li, C., Huang, W., Li, B., Strome, S., and Wang, L.-X. (2008). Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and In Vitro Chemoenzymatic Glycosylation. Biochemistry 47 (39), 10294–10304. doi:10.1021/bi800874y

Witte, K., Sears, P., Martin, R., and Wong, C.-H. (1997). Enzymatic Glycoprotein Synthesis: Preparation of Ribonucleoside Glycoforms via Enzymatic Glycopeptide Condensation and Glycosylation. J. Am. Chem. Soc. 119 (9), 2114–2118. doi:10.1021/ja961846z

Wong, C.-H., Wu, C.-Y., and Tsai, M.-H. (2015). Anti-CD20 Glycoantibodies and Uses of Thereof. USA patent application.

Yamaguchi, T., Amin, M. N., Toonstra, C., and Wang, L.-X. (2016). Chemoenzymatic Synthesis and Receptor Binding of Mannose-6-Phosphate (M6P)-Containing Glycoprotein Ligands Reveal Unusual Structural Requirements for M6P Receptor Recognition. J. Am. Chem. Soc. 138 (36), 12472–12485. doi:10.1021/jacs.6b05762

Yamane-Ohnuki, N., Kinosita, S., Inoue-Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., et al. (2004). Establishment of FTU8 Knockout Chinese Hamster Ocuvary Cell: An Ideal Host Cell Line for Producing Completely Defucosylated Antibodies with Enhanced Antibody-dependent Cellular Cytotoxicity. Biotechnol. Bioeng. 87 (5), 614–622. doi:10.1002/bit.20151

Zhao, K., Tang, F., Shi, W., Hong, H., Zhou, Z., Huang, W., et al. (2019). One-step Immobilization and Purification of Genetic Engineering CBD Fusion EndoS on Cellulose for Antibodies Fc-Glycan Remodeling. Bioorg. Med. Chem. 91, 103114. doi:10.1021/acs.bioconjchem.9b00314

Zhou, Y., Yuan, S., Liu, Q., Yan, D., Wang, Y., Gao, L., et al. (2017). Synchronized Purification and Immobilization of His-Tagged β-glucosidase via Fe3O4/PMG Core/shell Magnetic Nanoparticles. Sci. Rep. 7, 41741. doi:10.1038/srep41741

Conflict of Interest: AI was employed by AstraZeneca when this review was being prepared. FF is currently employed by AstraZeneca. This study received funding from AstraZeneca. The funder had the following involvement with the study: supporting the publication of the review.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editor, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ivanova and Falcioni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.